Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. Among authors: stander s. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Perceived Stigmatization among Dermatological Outpatients Compared with Controls: An Observational Multicentre Study in 17 European Countries.
Van Beugen S, Schut C, Kupfer J, Bewley AP, Finlay AY, Gieler U, Thompson AR, Gracia-Cazaña T, Balieva F, Ferreira BR, Jemec GB, Lien L, Misery L, Marron SE, Ständer S, Zeidler C, Szabó C, Szepietowski JC, Reich A, Elyas A, Altunay IK, Legat FJ, Grivcheva-Panovska V, Romanov DV, Lvov AN, Titeca G, Sampogna F, Vulink NC, Tomás-Aragones L, Evers AWM, Dalgard FJ; European Society for Dermatology and Psychiatry (ESDaP) Study collaborators. Van Beugen S, et al. Among authors: stander s. Acta Derm Venereol. 2023 Jun 22;103:adv6485. doi: 10.2340/actadv.v103.6485. Acta Derm Venereol. 2023. PMID: 37345973 Free PMC article.
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
Guttman-Yassky E, Silverberg JI, Thaçi D, Papp KA, Ständer S, Beck LA, Kim BS, Hu X, Liu J, Calimlim BM, Vigna N, Crowley JT, Teixeira HD, Thyssen JP. Guttman-Yassky E, et al. Among authors: stander s. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2558-2568. doi: 10.1111/jdv.19391. Epub 2023 Aug 26. J Eur Acad Dermatol Venereol. 2023. PMID: 37528500 Clinical Trial.
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
Yosipovitch G, Lio PA, Rosmarin D, Serra-Baldrich E, Legat FJ, Casillas M, Pierce E, Liu Z, Sun L, Elmaraghy H, Ständer S. Yosipovitch G, et al. Among authors: stander s. Br J Dermatol. 2024 Jan 23;190(2):289-291. doi: 10.1093/bjd/ljad435. Br J Dermatol. 2024. PMID: 37939793 Clinical Trial. No abstract available.
Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
Thyssen JP, Bewley A, Ständer S, Castro C, Misery L, Kim BS, Biswas P, Chan G, Myers DE, Watkins M, Alderfer J, Güler E, Silverberg JI. Thyssen JP, et al. Among authors: stander s. Dermatology. 2024;240(2):243-253. doi: 10.1159/000535285. Epub 2023 Dec 11. Dermatology. 2024. PMID: 38081155 Free PMC article. Clinical Trial.
486 results